Cat. No.: HY-100429

CAN508

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC₅₀ of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity.

For research use only. We do not sell to patients.

Purity: 99.71%
CAS No.: 140651-18-9
Formula: C₉H₁₀N₆O
Molecular Weight:218.22

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

CAN508 Chemical Structure

CAS No.: 140651-18-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

CDK9/cyclinT1

0.35 μM (IC₅₀)

CDK2/cyclinE

20 μM (IC₅₀)

cdk2/cyclin A

69 μM (IC₅₀)

Cdk4/cyclin D1

13.5 μM (IC₅₀)

CDK7/cyclin H

26 μM (IC₅₀)

Cdk1/cyclin B

44 μM (IC₅₀)

All CDK Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	GI₅₀	26.2 μM Compound: CAN508	Cytotoxicity against human 786-0 cells Cytotoxicity against human 786-0 cells	[PMID: 21777997]
A498	GI₅₀	18.2 μM Compound: CAN508	Cytotoxicity against human A498 cells Cytotoxicity against human A498 cells	[PMID: 21777997]
A549	GI₅₀	22.5 μM Compound: CAN508	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 21777997]
ACHN	GI₅₀	15.6 μM Compound: CAN508	Cytotoxicity against human ACHN cells Cytotoxicity against human ACHN cells	[PMID: 21777997]
BT-549	GI₅₀	14 μM Compound: CAN508	Cytotoxicity against human BT549 cells Cytotoxicity against human BT549 cells	[PMID: 21777997]
CAKI-1	GI₅₀	14.8 μM Compound: CAN508	Cytotoxicity against human Caki1 cells Cytotoxicity against human Caki1 cells	[PMID: 21777997]
CCRF-CEM	GI₅₀	20 μM Compound: CAN508	Cytotoxicity against human CCRF-CEM cells Cytotoxicity against human CCRF-CEM cells	[PMID: 21777997]
COLO 205	GI₅₀	18.9 μM Compound: CAN508	Cytotoxicity against human COLO205 cells Cytotoxicity against human COLO205 cells	[PMID: 21777997]
DU-145	GI₅₀	17 μM Compound: CAN508	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 21777997]
EKVX	GI₅₀	22 μM Compound: CAN508	Cytotoxicity against human EKVX cells Cytotoxicity against human EKVX cells	[PMID: 21777997]
G-361	IC₅₀	64 μM Compound: 31b, (CAN508)	Antiproliferative activity against G361 cell line Antiproliferative activity against G361 cell line	[PMID: 17064068]
HCC 2998	GI₅₀	29.4 μM Compound: CAN508	Cytotoxicity against human HCC2998 cells Cytotoxicity against human HCC2998 cells	[PMID: 21777997]
HCT-116	GI₅₀	18.9 μM Compound: CAN508	Cytotoxicity against human HCT116 cells Cytotoxicity against human HCT116 cells	[PMID: 21777997]
HCT-15	GI₅₀	24.2 μM Compound: CAN508	Cytotoxicity against human HCT15 cells Cytotoxicity against human HCT15 cells	[PMID: 21777997]
HL-60(TB)	GI₅₀	6.4 μM Compound: CAN508	Cytotoxicity against human HL-60(TB) cells Cytotoxicity against human HL-60(TB) cells	[PMID: 21777997]
HMEC-1	IC₅₀	20 μM Compound: CAN508	Inhibition of RNA synthesis in human HMEC1 cells assessed as decrease in [3H] Uridine incorporation after 2 hrs by scintillation counting Inhibition of RNA synthesis in human HMEC1 cells assessed as decrease in [3H] Uridine incorporation after 2 hrs by scintillation counting	[PMID: 21777997]
HOP-62	GI₅₀	31.8 μM Compound: CAN508	Cytotoxicity against human HOP62 cells Cytotoxicity against human HOP62 cells	[PMID: 21777997]
HOP-92	GI₅₀	18.2 μM Compound: CAN508	Cytotoxicity against human HOP92 cells Cytotoxicity against human HOP92 cells	[PMID: 21777997]
HOS	IC₅₀	49 μM Compound: 31b, (CAN508)	Antiproliferative activity against HOS cell line Antiproliferative activity against HOS cell line	[PMID: 17064068]
Hs-578T	GI₅₀	21.8 μM Compound: CAN508	Cytotoxicity against human Hs 578T cells Cytotoxicity against human Hs 578T cells	[PMID: 21777997]
HT-29	GI₅₀	29.7 μM Compound: CAN508	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 21777997]
IGROV-1	GI₅₀	20.6 μM Compound: CAN508	Cytotoxicity against human IGROV1 cells Cytotoxicity against human IGROV1 cells	[PMID: 21777997]
K562	GI₅₀	9.2 μM Compound: CAN508	Cytotoxicity against human K562 cells Cytotoxicity against human K562 cells	[PMID: 21777997]
K562	IC₅₀	33 μM Compound: IIIa, CAN508	Cytotoxicity against human K562 cells after 72 hrs by calcein AM staining-based fluorescence assay Cytotoxicity against human K562 cells after 72 hrs by calcein AM staining-based fluorescence assay	[PMID: 25835357]
K562	IC₅₀	62 μM Compound: 31b, (CAN508)	Antiproliferative activity against K562 cell line Antiproliferative activity against K562 cell line	[PMID: 17064068]
KM12	GI₅₀	17.1 μM Compound: CAN508	Cytotoxicity against human KM12 cells Cytotoxicity against human KM12 cells	[PMID: 21777997]
LOX IMVI	GI₅₀	4.1 μM Compound: CAN508	Cytotoxicity against human LOXIMVI cells Cytotoxicity against human LOXIMVI cells	[PMID: 21777997]
M14	GI₅₀	15.9 μM Compound: CAN508	Cytotoxicity against human M14 cells Cytotoxicity against human M14 cells	[PMID: 21777997]
Malme-3M	GI₅₀	24.5 μM Compound: CAN508	Cytotoxicity against human MALME-3M cells Cytotoxicity against human MALME-3M cells	[PMID: 21777997]
MCF7	GI₅₀	23.5 μM Compound: CAN508	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 21777997]
MCF7	IC₅₀	15 μM Compound: CAN508	Inhibition of RNA synthesis in human MCF7 cells assessed as decrease in [3H] Uridine incorporation after 2 hrs by scintillation counting Inhibition of RNA synthesis in human MCF7 cells assessed as decrease in [3H] Uridine incorporation after 2 hrs by scintillation counting	[PMID: 21777997]
MCF7	IC₅₀	33 μM Compound: 31b, (CAN508)	Antiproliferative activity against MCF7 cell line Antiproliferative activity against MCF7 cell line	[PMID: 17064068]
MCF7	IC₅₀	62 μM Compound: IIIa, CAN508	Cytotoxicity against human MCF7 cells after 72 hrs by calcein AM staining-based fluorescence assay Cytotoxicity against human MCF7 cells after 72 hrs by calcein AM staining-based fluorescence assay	[PMID: 25835357]
MDA-MB-231	GI₅₀	16.7 μM Compound: CAN508	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 21777997]
MDA-MB-435	GI₅₀	17.1 μM Compound: CAN508	Cytotoxicity against human MDA-MB-435 cells Cytotoxicity against human MDA-MB-435 cells	[PMID: 21777997]
MOLT-4	GI₅₀	13.5 μM Compound: CAN508	Cytotoxicity against human MOLT4 cells Cytotoxicity against human MOLT4 cells	[PMID: 21777997]
NCI/ADR-RES	GI₅₀	22.5 μM Compound: CAN508	Cytotoxicity against human NCI/ADR-RES cells Cytotoxicity against human NCI/ADR-RES cells	[PMID: 21777997]
NCI-H226	GI₅₀	17.7 μM Compound: CAN508	Cytotoxicity against human NCI-H226 cells Cytotoxicity against human NCI-H226 cells	[PMID: 21777997]
NCI-H23	GI₅₀	19.1 μM Compound: CAN508	Cytotoxicity against human NCI-H23 cells Cytotoxicity against human NCI-H23 cells	[PMID: 21777997]
NCI-H322M	GI₅₀	25.1 μM Compound: CAN508	Cytotoxicity against human NCI-H322M cells Cytotoxicity against human NCI-H322M cells	[PMID: 21777997]
NCI-H460	GI₅₀	25.1 μM Compound: CAN508	Cytotoxicity against human NCI-H460 cells Cytotoxicity against human NCI-H460 cells	[PMID: 21777997]
NCI-H522	GI₅₀	24.3 μM Compound: CAN508	Cytotoxicity against human NCI-H522 cells Cytotoxicity against human NCI-H522 cells	[PMID: 21777997]
OVCAR-3	GI₅₀	22.8 μM Compound: CAN508	Cytotoxicity against human OVCAR3 cells Cytotoxicity against human OVCAR3 cells	[PMID: 21777997]
OVCAR-4	GI₅₀	19 μM Compound: CAN508	Cytotoxicity against human OVCAR4 cells Cytotoxicity against human OVCAR4 cells	[PMID: 21777997]
OVCAR-5	GI₅₀	23.5 μM Compound: CAN508	Cytotoxicity against human OVCAR5 cells Cytotoxicity against human OVCAR5 cells	[PMID: 21777997]
OVCAR-8	GI₅₀	18 μM Compound: CAN508	Cytotoxicity against human OVCAR8 cells Cytotoxicity against human OVCAR8 cells	[PMID: 21777997]
PC-3	GI₅₀	20.3 μM Compound: CAN508	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 21777997]
RPMI-8226	GI₅₀	14.4 μM Compound: CAN508	Cytotoxicity against human RPMI8226 cells Cytotoxicity against human RPMI8226 cells	[PMID: 21777997]
RPMI-8226	IC₅₀	24.9 μM Compound: IIIa, CAN508	Cytotoxicity against human RPMI8226 cells after 72 hrs by calcein AM staining-based fluorescence assay Cytotoxicity against human RPMI8226 cells after 72 hrs by calcein AM staining-based fluorescence assay	[PMID: 25835357]
RXF 393	GI₅₀	18.4 μM Compound: CAN508	Cytotoxicity against human RXF393 cells Cytotoxicity against human RXF393 cells	[PMID: 21777997]
SF-268	GI₅₀	20.6 μM Compound: CAN508	Cytotoxicity against human SF268 cells Cytotoxicity against human SF268 cells	[PMID: 21777997]
SF-295	GI₅₀	23.3 μM Compound: CAN508	Cytotoxicity against human SF295 cells Cytotoxicity against human SF295 cells	[PMID: 21777997]
SF-539	GI₅₀	13.2 μM Compound: CAN508	Cytotoxicity against human SF539 cells Cytotoxicity against human SF539 cells	[PMID: 21777997]
Sf9	IC₅₀	0.35 μM Compound: IIIa, CAN508	Inhibition of CDK9/cyclin T1 (unknown origin) expressed in baculovirus infected Sf9 cells Inhibition of CDK9/cyclin T1 (unknown origin) expressed in baculovirus infected Sf9 cells	[PMID: 25835357]
Sf9	IC₅₀	13.5 μM Compound: IIIa, CAN508	Inhibition of CDK4/cyclin D1 (unknown origin) expressed in baculovirus infected Sf9 cells Inhibition of CDK4/cyclin D1 (unknown origin) expressed in baculovirus infected Sf9 cells	[PMID: 25835357]
Sf9	IC₅₀	20 μM Compound: IIIa, CAN508	Inhibition of CDK2/cyclin E (unknown origin) expressed in baculovirus infected Sf9 cells Inhibition of CDK2/cyclin E (unknown origin) expressed in baculovirus infected Sf9 cells	[PMID: 25835357]
Sf9	IC₅₀	26 μM Compound: IIIa, CAN508	Inhibition of CDK7/cyclin H (unknown origin) expressed in baculovirus infected Sf9 cells Inhibition of CDK7/cyclin H (unknown origin) expressed in baculovirus infected Sf9 cells	[PMID: 25835357]
Sf9	IC₅₀	44 μM Compound: IIIa, CAN508	Inhibition of CDK1/cyclin B (unknown origin) expressed in baculovirus infected Sf9 cells Inhibition of CDK1/cyclin B (unknown origin) expressed in baculovirus infected Sf9 cells	[PMID: 25835357]
SK-MEL-2	GI₅₀	14.4 μM Compound: CAN508	Cytotoxicity against human SK-MEL-2 cells Cytotoxicity against human SK-MEL-2 cells	[PMID: 21777997]
SK-MEL-28	GI₅₀	22.1 μM Compound: CAN508	Cytotoxicity against human SK-MEL-28 cells Cytotoxicity against human SK-MEL-28 cells	[PMID: 21777997]
SK-MEL-5	GI₅₀	13.9 μM Compound: CAN508	Cytotoxicity against human SK-MEL-5 cells Cytotoxicity against human SK-MEL-5 cells	[PMID: 21777997]
SK-OV-3	GI₅₀	49.2 μM Compound: CAN508	Cytotoxicity against human SKOV3 cells Cytotoxicity against human SKOV3 cells	[PMID: 21777997]
SN12C	GI₅₀	23.3 μM Compound: CAN508	Cytotoxicity against human SN12C cells Cytotoxicity against human SN12C cells	[PMID: 21777997]
SNB-19	GI₅₀	29.9 μM Compound: CAN508	Cytotoxicity against human SNB19 cells Cytotoxicity against human SNB19 cells	[PMID: 21777997]
SNB-75	GI₅₀	18.5 μM Compound: CAN508	Cytotoxicity against human SNB75 cells Cytotoxicity against human SNB75 cells	[PMID: 21777997]
SR	GI₅₀	10.3 μM Compound: CAN508	Cytotoxicity against human SR cells Cytotoxicity against human SR cells	[PMID: 21777997]
SW-620	GI₅₀	26.3 μM Compound: CAN508	Cytotoxicity against human SW620 cells Cytotoxicity against human SW620 cells	[PMID: 21777997]
T47D	GI₅₀	14.2 μM Compound: CAN508	Cytotoxicity against human T47D cells Cytotoxicity against human T47D cells	[PMID: 21777997]
TK-10	GI₅₀	25.6 μM Compound: CAN508	Cytotoxicity against human TK10 cells Cytotoxicity against human TK10 cells	[PMID: 21777997]
U-251	GI₅₀	21.2 μM Compound: CAN508	Cytotoxicity against human U251 cells Cytotoxicity against human U251 cells	[PMID: 21777997]
UACC-257	GI₅₀	24.4 μM Compound: CAN508	Cytotoxicity against human UACC257 cells Cytotoxicity against human UACC257 cells	[PMID: 21777997]
UACC-62	GI₅₀	11 μM Compound: CAN508	Cytotoxicity against human UACC62 cells Cytotoxicity against human UACC62 cells	[PMID: 21777997]
UO-31	GI₅₀	13.7 μM Compound: CAN508	Cytotoxicity against human UO31 cells Cytotoxicity against human UO31 cells	[PMID: 21777997]

In Vitro

CAN508 reduces the frequency of S-phase cells of the cancer cell line HT-29 in antiproliferation assays^[1].
CAN508 (20-40 μM; 72 hours) significantly reduces cell proliferation in a dose dependent manner in all three esophageal adenocarcinoma cell lines (SKGT4, OE33 and FLO-1 cells) with IC₅₀s ranging from 34.99 to 91.09 μM^[2].
CAN508 (40 μM; 72 hours) increases apoptosis in all three esophageal adenocarcinoma cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:

SKGT4, OE33 and FLO-1 cells
Concentration:

40 μM
Incubation Time:

72 hours
Result:

Increased apoptosis by 2 fold in all three esophageal adenocarcinoma cells compared to untreated controls.

In Vivo

CAN508 (60 mg/kg; i.p.; daily for 10 days) has antitumor effects in esophageal adenocarcinoma xenografts^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

4 weeks-old female nude mice (esophageal adenocarcinoma xenografts)^[1]
Dosage:

60 mg/kg
Administration:

I.p.; daily for 10 days
Result:

Caused reduction of tumor growth starting from post-treatment day three with 50.83% reduction.

Chemical Information

CAS No. 140651-18-9
Appearance Solid
Molecular Weight 218.22
Formula C₉H₁₀N₆O
Color Light yellow to yellow
SMILES

OC1=CC=C(/N=N/C2=C(N)NN=C2N)C=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Universidade de Lisboa

2021 Dec 21.

Solvent & Solubility

In Vitro:

DMSO : 250 mg/mL (1145.63 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.5825 mL

22.9127 mL

45.8253 mL

5 mM

0.9165 mL

4.5825 mL

9.1651 mL

10 mM

0.4583 mL

2.2913 mL

4.5825 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (9.53 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Krystof V, et al. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006;49(22):6500-6509. [Content Brief]

[2]. Tong Z, et al. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017;8(17):28696-28710. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.5825 mL	22.9127 mL	45.8253 mL	114.5633 mL
	5 mM	0.9165 mL	4.5825 mL	9.1651 mL	22.9127 mL
	10 mM	0.4583 mL	2.2913 mL	4.5825 mL	11.4563 mL
	15 mM	0.3055 mL	1.5275 mL	3.0550 mL	7.6376 mL
	20 mM	0.2291 mL	1.1456 mL	2.2913 mL	5.7282 mL
	25 mM	0.1833 mL	0.9165 mL	1.8330 mL	4.5825 mL
	30 mM	0.1528 mL	0.7638 mL	1.5275 mL	3.8188 mL
	40 mM	0.1146 mL	0.5728 mL	1.1456 mL	2.8641 mL
	50 mM	0.0917 mL	0.4583 mL	0.9165 mL	2.2913 mL
	60 mM	0.0764 mL	0.3819 mL	0.7638 mL	1.9094 mL
	80 mM	0.0573 mL	0.2864 mL	0.5728 mL	1.4320 mL
	100 mM	0.0458 mL	0.2291 mL	0.4583 mL	1.1456 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

CAN508

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) CAN508

All CDK Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

CAN508

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) CAN508

All CDK Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

CAN508 Related Classifications

HY-100429 Related Classifications